DBV Technologies S.A.
DBV Technologies S.A., a pioneering biopharmaceutical company headquartered in France, focuses on developing innovative treatments for food allergies and other immune-mediated diseases. Founded in 2002, the company has made significant strides in the field of immunotherapy, particularly with its proprietary Viaskin® technology, which offers a unique, non-invasive method for delivering therapeutic proteins through the skin. With a strong presence in Europe and North America, DBV Technologies is recognised for its commitment to advancing patient care through its core product offerings, including the Viaskin Peanut patch, designed to desensitise individuals with peanut allergies. The company has achieved notable milestones, including successful clinical trials and partnerships that enhance its market position in the biopharmaceutical industry. As a leader in allergy treatment innovation, DBV Technologies continues to shape the future of immunotherapy.
DitchCarbon Score
How does DBV Technologies S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DBV Technologies S.A.'s score of 28 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
DBV Technologies S.A.'s reported carbon emissions
DBV Technologies S.A., headquartered in France, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or commitments to the Science Based Targets initiative (SBTi) or other climate pledges. As there is no available data on their carbon footprint or reduction initiatives, it is unclear how DBV Technologies S.A. is addressing climate change within its operations. The lack of emissions reporting may suggest that the company is in the early stages of developing its climate strategy or is yet to publicly disclose its environmental impact. In the context of the biotechnology industry, companies are increasingly recognising the importance of sustainability and are often encouraged to set measurable targets for reducing greenhouse gas emissions. However, without specific commitments or data, it is difficult to assess DBV Technologies S.A.'s position in this regard.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DBV Technologies S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
